Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stanley K. Mui is active.

Publication


Featured researches published by Stanley K. Mui.


Journal of Experimental Medicine | 2004

Loss of HIV-1–specific CD8+ T Cell Proliferation after Acute HIV-1 Infection and Restoration by Vaccine-induced HIV-1–specific CD4+ T Cells

Mathias Lichterfeld; Daniel E. Kaufmann; Xu G. Yu; Stanley K. Mui; Marylyn M. Addo; Mary N. Johnston; Daniel E. Cohen; Gregory K. Robbins; Eunice Pae; Galit Alter; Alysse Wurcel; David Stone; Eric S. Rosenberg; Bruce D. Walker; Marcus Altfeld

Virus-specific CD8+ T cells are associated with declining viremia in acute human immunodeficiency virus (HIV)1 infection, but do not correlate with control of viremia in chronic infection, suggesting a progressive functional defect not measured by interferon γ assays presently used. Here, we demonstrate that HIV-1–specific CD8+ T cells proliferate rapidly upon encounter with cognate antigen in acute infection, but lose this capacity with ongoing viral replication. This functional defect can be induced in vitro by depletion of CD4+ T cells or addition of interleukin 2–neutralizing antibodies, and can be corrected in chronic infection in vitro by addition of autologous CD4+ T cells isolated during acute infection and in vivo by vaccine-mediated induction of HIV-1–specific CD4+ T helper cell responses. These data demonstrate a loss of HIV-1–specific CD8+ T cell function that not only correlates with progressive infection, but also can be restored in chronic infection by augmentation of HIV-1–specific T helper cell function. This identification of a reversible defect in cell-mediated immunity in chronic HIV-1 infection has important implications for immunotherapeutic interventions.


Journal of Virology | 2005

De Novo Generation of Escape Variant-Specific CD8+ T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human Immunodeficiency Virus Type 1 Infection

Todd M. Allen; Xu G. Yu; Elizabeth T. Kalife; Laura L. Reyor; Mathias Lichterfeld; M. John; Michael Cheng; Rachel L. Allgaier; Stanley K. Mui; Nicole Frahm; Galit Alter; Nancy V. Brown; Mary N. Johnston; Eric S. Rosenberg; S. Mallal; Christian Brander; Bruce D. Walker; Marcus Altfeld

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) evades CD8+ T-cell responses through mutations within targeted epitopes, but little is known regarding its ability to generate de novo CD8+ T-cell responses to such mutants. Here we examined gamma interferon-positive, HIV-1-specific CD8+ T-cell responses and autologous viral sequences in an HIV-1-infected individual for more than 6 years following acute infection. Fourteen optimal HIV-1 T-cell epitopes were targeted by CD8+ T cells, four of which underwent mutation associated with dramatic loss of the original CD8+ response. However, following the G357S escape in the HLA-A11-restricted Gag349-359 epitope and the decline of wild-type-specific CD8+ T-cell responses, a novel CD8+ T-cell response equal in magnitude to the original response was generated against the variant epitope. CD8+ T cells targeting the variant epitope did not exhibit cross-reactivity against the wild-type epitope but rather utilized a distinct T-cell receptor Vβ repertoire. Additional studies of chronically HIV-1-infected individuals expressing HLA-A11 demonstrated that the majority of the subjects targeted the G357S escape variant of the Gag349-359 epitope, while the wild-type consensus sequence was significantly less frequently recognized. These data demonstrate that de novo responses against escape variants of CD8+ T-cell epitopes can be generated in chronic HIV-1 infection and provide the rationale for developing vaccines to induce CD8+ T-cell responses directed against both the wild-type and variant forms of CD8 epitopes to prevent the emergence of cytotoxic T-lymphocyte escape variants.


Journal of Virology | 2007

Selective Depletion of High-Avidity Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+ T Cells after Early HIV-1 Infection

Mathias Lichterfeld; Xu G. Yu; Stanley K. Mui; Katie Williams; Alicja Trocha; Mark A. Brockman; Rachel L. Allgaier; Michael T. Waring; Tomohiko Koibuchi; Mary N. Johnston; Daniel E. Cohen; Todd M. Allen; Eric S. Rosenberg; Bruce D. Walker; Marcus Altfeld

ABSTRACT Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells in early infection are associated with the dramatic decline of peak viremia, whereas their antiviral activity in chronic infection is less apparent. The functional properties accounting for the antiviral activity of HIV-1-specific CD8+ T cells during early infection are unclear. Using cytokine secretion and tetramer decay assays, we demonstrated in intraindividual comparisons that the functional avidity of HIV-1-specific CD8+ T cells was consistently higher in early infection than in chronic infection in the presence of high-level viral replication. This change of HIV-1-specific CD8+ T-cell avidity between early and chronic infections was linked to a substantial switch in the clonotypic composition of epitope-specific CD8+ T cells, resulting from the preferential loss of high-avidity CD8+ T-cell clones. In contrast, the maintenance of the initially recruited clonotypic pattern of HIV-1-specific CD8+ T cells was associated with low-level set point HIV-1 viremia. These data suggest that high-avidity HIV-1-specific CD8+ T-cell clones are recruited during early infection but are subsequently lost in the presence of persistent high-level viral replication.


Journal of Experimental Medicine | 2007

A viral CTL escape mutation leading to immunoglobulin-like transcript 4 - mediated functional inhibition of myelomonocytic cells

Mathias Lichterfeld; Daniel G. Kavanagh; Katie Williams; Beenu Moza; Stanley K. Mui; Toshiyuki Miura; Rohini Sivamurthy; Rachel L. Allgaier; Florencia Pereyra; Alicja Trocha; Margaret E. Feeney; Rajesh T. Gandhi; Eric S. Rosenberg; Marcus Altfeld; Todd M. Allen; Rachel L. Allen; Bruce D. Walker; Eric J. Sundberg; Xu G. Yu

Viral mutational escape can reduce or abrogate recognition by the T cell receptor (TCR) of virus-specific CD8+ T cells. However, very little is known about the impact of cytotoxic T lymphocyte (CTL) epitope mutations on interactions between peptide–major histocompatibility complex (MHC) class I complexes and MHC class I receptors expressed on other cell types. Here, we analyzed a variant of the immunodominant human leukocyte antigen (HLA)-B2705–restricted HIV-1 Gag KK10 epitope (KRWIILGLNK) with an L to M amino acid substitution at position 6 (L6M), which arises as a CTL escape variant after primary infection but is sufficiently immunogenic to elicit a secondary, de novo HIV-1–specific CD8+ T cell response with an alternative TCR repertoire in chronic infection. In addition to altering recognition by HIV-1–specific CD8+ T cells, the HLA-B2705–KK10 L6M complex also exhibits substantially increased binding to the immunoglobulin-like transcript (ILT) receptor 4, an inhibitory MHC class I–specific receptor expressed on myelomonocytic cells. Binding of the B2705–KK10 L6M complex to ILT4 leads to a tolerogenic phenotype of myelomonocytic cells with lower surface expression of dendritic cell (DC) maturation markers and co-stimulatory molecules. These data suggest a link between CTL-driven mutational escape, altered recognition by innate MHC class I receptors on myelomonocytic cells, and functional impairment of DCs, and thus provide important new insight into biological consequences of viral sequence diversification.


Journal of Virology | 2007

Mutually Exclusive T-Cell Receptor Induction and Differential Susceptibility to Human Immunodeficiency Virus Type 1 Mutational Escape Associated with a Two-Amino-Acid Difference between HLA Class I Subtypes

Xu G. Yu; Mathias Lichterfeld; Senica Chetty; Katie Williams; Stanley K. Mui; Toshiyuki Miura; Nicole Frahm; Margaret E. Feeney; Yanhua Tang; Florencia Pereyra; Montiago X. LaBute; K. Pfafferott; Alisdair Leslie; Hayley Crawford; Rachel L. Allgaier; William H. Hildebrand; Richard A. Kaslow; Christian Brander; Todd M. Allen; Eric S. Rosenberg; Photini Kiepiela; Madhu Vajpayee; Paul A. Goepfert; Marcus Altfeld; Philip J. R. Goulder; Bruce D. Walker

ABSTRACT The relative contributions of HLA alleles and T-cell receptors (TCRs) to the prevention of mutational viral escape are unclear. Here, we examined human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses restricted by two closely related HLA class I alleles, B*5701 and B*5703, that differ by two amino acids but are both associated with a dominant response to the same HIV-1 Gag epitope KF11 (KAFSPEVIPMF). When this epitope is presented by HLA-B*5701, it induces a TCR repertoire that is highly conserved among individuals, cross-recognizes viral epitope variants, and is rarely associated with mutational escape. In contrast, KF11 presented by HLA-B*5703 induces an entirely different, more heterogeneous TCR β-chain repertoire that fails to recognize specific KF11 escape variants which frequently arise in clade C-infected HLA-B*5703+ individuals. These data show the influence of HLA allele subtypes on TCR selection and indicate that extensive TCR diversity is not a prerequisite to prevention of allowable viral mutations.


Journal of Virology | 2005

Limited Sequence Evolution within Persistently Targeted CD8 Epitopes in Chronic Human Immunodeficiency Virus Type 1 Infection

Tomohiko Koibuchi; Todd M. Allen; Mathias Lichterfeld; Stanley K. Mui; Kristin M. O'Sullivan; Alicja Trocha; Spyros A. Kalams; R. Paul Johnson; Bruce D. Walker

ABSTRACT Studies in acute human immunodeficiency virus type 1 (HIV-1) infection indicate viral evolution under CD8 T-cell immune selection pressure, but the effects of ongoing immune pressure on epitope evolution during chronic infection are not well described. In this study, we performed a detailed longitudinal analysis of viral sequence variation within persistently targeted cytotoxic T-lymphocyte (CTL) epitopes in two HIV-1-infected persons during 6 years of persistent viremia. Responses were quantitated using freshly isolated peripheral blood lymphocytes in direct lytic assays as well as by gamma interferon (IFN-γ) Elispot assays on cryopreserved cells. Seven targeted epitopes were identified in each person. In the majority of cases, the dominant epitope sequence did not change over time, even in the presence of responses of sufficient magnitude that they were detectable using fresh peripheral blood mononuclear cells in direct lytic assays. Only 4 of the 14 autologous epitopes tested represented potential CTL escape variants; however, in most cases strong responses to these epitopes persisted for the 6 years of study. Although persistent IFN-γ responses were detected to all epitopes, direct lytic assays demonstrated declining responses to some epitopes despite the persistence of the targeted sequence in vivo. These data indicate limited viral evolution within persistently targeted CD8 T-cell epitopes during the chronic phase of infection and suggest that these regions of the virus are either refractory to sequence change or that persistently activated CD8 T-cell responses in chronic infection exert little functional selection pressure.


AIDS | 2005

High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level.

Xu G. Yu; Mathias Lichterfeld; Beth Perkins; Elizabeth T. Kalife; Stanley K. Mui; Jianping Chen; Michael Cheng; Wenzhen Kang; Galit Alter; Christian Brander; Bruce D. Walker; Marcus Altfeld

Objectives:To determine HIV-1-specific T cell responses in clade B infected individuals recognizing the clade A, B and C consensus sequences in order to assess the degree of inter-clade cross-reactivity of these immune responses at the single epitope level. Methods:HIV-1-specific T cell responses were assessed cross-sectionally in 27 chronically HIV-1-infected individuals from a population infected mainly with clade B viral strains, using an interferon-γ Elispot assay with a total of 1230 overlapping peptides spanning the entire amino acid sequence of the clade A, B and C 2001 consensus sequences. Results:No significant difference was observed between the total magnitude or breadth of T cell responses recognizing either the clade A, B or C consensus sequences. However, at the single peptide level, 194 T cell responses were identified that recognized only one of the three different clade-specific peptide variants (A: B: C, 34: 105: 55), 125 T cell responses recognized two of the three peptide variants (AB: AC: BC, 71: 15: 39) and 166 T cell responses (34%) were cross-reactive with all three different peptide variants. Peptides recognized in all three consensus sequence variants had a significantly lower entropy (P < 0.0001) and a significantly higher inter-clade homology (P < 0.0001). Conclusions:Viral epitopes within regions of low HIV-1 clade B diversity and high inter-clade homology can be recognized in the clade A, B and C variants and indicate a wide degree of cross-isolate and cross-clade recognition by HIV-1-specific T cells. These regions may therefore be of particular relevance for the design of HIV-1 vaccines.


Blood | 2004

HIV-1–specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-γ and tumor necrosis factor–α

Mathias Lichterfeld; Xu G. Yu; Michael T. Waring; Stanley K. Mui; Mary N. Johnston; Daniel E. Cohen; Marylyn M. Addo; John Zaunders; Galit Alter; Eunice Pae; Daryld Strick; Todd M. Allen; Eric S. Rosenberg; Bruce D. Walker; Marcus Altfeld


International Immunology | 2006

T cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related alleles from the HLA-A3 superfamily

Mathias Lichterfeld; Katie Williams; Stanley K. Mui; Shivani S. Shah; Bianca R. Mothé; Alessandro Sette; Arthur Y. Kim; Mary N. Johnston; Nicole C. Burgett; Nicole Frahm; Daniel E. Cohen; Christian Brander; Eric S. Rosenberg; Bruce D. Walker; Marcus Altfeld; Xu G. Yu


Journal of Acquired Immune Deficiency Syndromes | 2012

Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.

Mathias Lichterfeld; Rajesh T. Gandhi; Rachel P. Simmons; Theresa Flynn; Amy Sbrolla; Xu G. Yu; Nesli Basgoz; Stanley K. Mui; Katie Williams; Hendrik Streeck; Nicole Burgett-Yandow; Gilbert Roy; Michel Janssens; Louise Pedneault; Pierre Vandepapelière; Marguerite Koutsoukos; Marie-Ange Demoitié; Patricia Bourguignon; Lisa McNally; Gerald Voss; Marcus Altfeld

Collaboration


Dive into the Stanley K. Mui's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nicole Frahm

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge